Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 23, 2023

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

February 22, 2023

Enveric Biosciences to Present at the BIO CEO & Investor Conference

February 1, 2023

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during “J.P. Morgan Health Care Week 2023”

December 21, 2022

Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

November 28, 2022

Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

November 16, 2022

Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022

November 1, 2022

Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

October 24, 2022

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

October 12, 2022

Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

August 31, 2022

‹
1
…
10
11
12
13
14
…
18
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.